Logo image of VRPX

VIRPAX PHARMACEUTICALS INC (VRPX) Stock Fundamental Analysis

NASDAQ:VRPX - Nasdaq - US9282512063 - Common Stock - Currency: USD

0.6695  -0.55 (-45.12%)

After market: 0.4498 -0.22 (-32.82%)

Fundamental Rating

0

Overall VRPX gets a fundamental rating of 0 out of 10. We evaluated VRPX against 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of VRPX have multiple concerns. VRPX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VRPX had negative earnings in the past year.
In the past year VRPX has reported a negative cash flow from operations.
In the past 5 years VRPX always reported negative net income.
In the past 5 years VRPX always reported negative operating cash flow.
VRPX Yearly Net Income VS EBIT VS OCF VS FCFVRPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -775.73%, VRPX is doing worse than 95.48% of the companies in the same industry.
Industry RankSector Rank
ROA -775.73%
ROE N/A
ROIC N/A
ROA(3y)-347.85%
ROA(5y)-401.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRPX Yearly ROA, ROE, ROICVRPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for VRPX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRPX Yearly Profit, Operating, Gross MarginsVRPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for VRPX has been increased compared to 1 year ago.
Compared to 5 years ago, VRPX has more shares outstanding
There is no outstanding debt for VRPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VRPX Yearly Shares OutstandingVRPX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M
VRPX Yearly Total Debt VS Total AssetsVRPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

VRPX has an Altman-Z score of -90.57. This is a bad value and indicates that VRPX is not financially healthy and even has some risk of bankruptcy.
VRPX has a worse Altman-Z score (-90.57) than 93.47% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -90.57
ROIC/WACCN/A
WACCN/A
VRPX Yearly LT Debt VS Equity VS FCFVRPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

VRPX has a Current Ratio of 0.63. This is a bad value and indicates that VRPX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.63, VRPX is not doing good in the industry: 92.96% of the companies in the same industry are doing better.
VRPX has a Quick Ratio of 0.63. This is a bad value and indicates that VRPX is not financially healthy enough and could expect problems in meeting its short term obligations.
VRPX has a worse Quick ratio (0.63) than 88.44% of its industry peers.
Industry RankSector Rank
Current Ratio 0.63
Quick Ratio 0.63
VRPX Yearly Current Assets VS Current LiabilitesVRPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

VRPX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.22%, which is quite impressive.
EPS 1Y (TTM)59.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-412.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, VRPX will show a very strong growth in Earnings Per Share. The EPS will grow by 22.53% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y81.21%
EPS Next 2Y35.96%
EPS Next 3Y22.53%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VRPX Yearly Revenue VS EstimatesVRPX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 50M 100M 150M
VRPX Yearly EPS VS EstimatesVRPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 -50 -100 -150 -200

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VRPX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRPX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRPX Price Earnings VS Forward Price EarningsVRPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRPX Per share dataVRPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -5 -10 -15

4.3 Compensation for Growth

VRPX's earnings are expected to grow with 22.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.96%
EPS Next 3Y22.53%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VRPX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIRPAX PHARMACEUTICALS INC

NASDAQ:VRPX (4/3/2025, 8:04:03 PM)

After market: 0.4498 -0.22 (-32.82%)

0.6695

-0.55 (-45.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-03 2025-03-03/amc
Earnings (Next)N/A N/A
Inst Owners0.72%
Inst Owner Change-76.9%
Ins Owners0.14%
Ins Owner Change0%
Market Cap856.96K
Analysts43.33
Price TargetN/A
Short Float %1.16%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-84.28%
Min EPS beat(2)-190.49%
Max EPS beat(2)21.93%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-2400%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1622.22%
EPS NY rev (3m)-1622.22%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-5.29
EYN/A
EPS(NY)-15.81
Fwd EYN/A
FCF(TTM)-13.06
FCFYN/A
OCF(TTM)-13.06
OCFYN/A
SpS0
BVpS-0.71
TBVpS-0.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -775.73%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-347.85%
ROA(5y)-401.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.63
Quick Ratio 0.63
Altman-Z -90.57
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-412.82%
EPS Next Y81.21%
EPS Next 2Y35.96%
EPS Next 3Y22.53%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-69.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-69.61%
OCF growth 3YN/A
OCF growth 5YN/A